Biotech Values

[vinmantoo]

It is pretty interesting reading about what the judge said in the hearing about the injunction filed by Sanofi and also how the FDA responded. Both sounded very like they bode well for MNTA. I also liked reading what the Medco had to say about what enoxoparin means to patient costs and to Medco. And yet the mythical "efficient market" keeps driving MNTA down. I wish to thank the "efficient market" for its gift, so I doubled my shares of MNTA today at $16.26. That is pretty easy to do since I didn't have that much (yet).